Omeros Corporation logo
Omeros Corporation OMER
$ 20.08 0.22%
report update icon

Quarterly report 2026-Q2
added 08-12-2026

Omeros Corporation Income Statement 2025-2008 | OMER

Brief overview of financial results at Omeros Corporation

This overview is based on financial performance over the past five years. According to figures from Omeros Corporation, revenue changed from $539 thousand to $112 million over five years. The cumulative result was +20643%, corresponding to roughly 190.7% per year. The annual growth rate indicates an exceptionally strong top-line trend.

Over the period, EBITDA shifted from −69.7 million dollars to −61.6 million dollars, a change of +11.6%. Changes in revenue did not translate into comparable EBITDA performance. Comparing the endpoints gives EBITDA margins of −12928% and −55.1%. Higher profitability strengthens the quality of operating growth.

Across the five years, the net result shifted from −$73.7 million to −$84.5 million. The loss widened and increased the financial risk.

The five-year change in capitalization reached −12.5%: from 739 million dollars to 647 million dollars. The market became more cautious about the prospects of the business.

What the figures show

Positive developments coexist with areas of weakness. The financial profile benefits from positive operating leverage and sales growth. The most visible risks are a narrow EBITDA buffer and declining net profitability. The next reporting periods will show whether revenue, margins, and final profitability can strengthen.

Annual Income Statement Omeros Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

671 M 478 M 200 M 215 M 401 M 817 M 647 M 636 M 755 M 375 M 405 M 739 M 342 M 133 M 129 M 118 M - -

Shares

63.5 M 58.2 M 62.7 M 62.7 M 62.3 M 57.2 M 49.5 M 48.6 M 45.5 M 40.4 M 37.6 M 33.2 M 28.6 M 24.2 M 22.2 M 21.4 M - -

Historical Prices

10.6 8.22 3.19 3.43 6.43 14.3 14.1 11.1 19.4 9.92 15.7 24.8 11.3 5.19 3.95 5.52 - -

Net Income

-3.35 M -157 M -118 M 47.4 M 194 M -138 M -84.5 M -127 M -53.5 M -66.7 M -75.1 M -73.7 M -39.8 M -38.4 M -28.5 M -29.3 M -21.1 M -

Revenue

- - - - - - 112 M 29.9 M 64.8 M 41.6 M 13.5 M 539 K 1.6 M 6.02 M 4.52 M 2.1 M 1.44 M -

Cost of Revenue

- - - - - - 865 K 512 K 1.08 M 1.41 M - - - - - - - -

Gross Profit

- - - - - - 111 M 29.4 M 63.7 M 40.2 M 12.5 M - - - 4.52 M - - -

Operating Income

-123 M -167 M -165 M -163 M -174 M -157 M -146 M -112 M -43.9 M -54.3 M -71.2 M -70 M -50.5 M -36.9 M -27.4 M -30.1 M -20.8 M -

Interest Expense

- - 30.8 M 22.7 M 19.7 M 26.8 M 22.7 M 16.3 M 11 M 7.82 M 3.57 M 3.47 M 2.37 M 1.73 M 1.88 M 1.54 M 2.2 M -

EBITDA

-122 M -166 M -164 M -162 M -172 M -155 M -61.6 M -111 M -43.3 M -54 M -71 M -69.7 M -50.2 M -36.6 M -27 M -29.6 M -20.3 M -

Operating Expenses

- - - - - - 174 M 142 M 108 M 94.5 M 83.7 M 70.5 M 52.1 M 42.9 M 31.9 M 32.2 M 22.2 M -

General and Administrative Expenses

41.5 M 47.4 M 49.7 M 50.7 M 54.8 M 49.3 M 64.6 M 51.7 M 52 M 43.8 M 35.3 M 22.6 M 15.8 M 11 M 8.22 M 8.75 M 5.27 M -

All numbers in USD currency

Quarterly Income Statement Omeros Corporation

2026-Q2 2026-Q1 2025-Q4 2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

58.6 M 71.9 M - 66.3 M 58.6 M 58.1 M 58 M 57.9 M 57.9 M 58.8 M 61.1 M 62.9 M 62.8 M 62.8 M 62.8 M 62.7 M 62.7 M 62.7 M 62.6 M 62.5 M 62.4 M 61.9 M 61.7 M 58.2 M 54.5 M 54.3 M 54.2 M 49.4 M 49.1 M 49 M 49 M 48.6 M 48.4 M 48.3 M 48.2 M 46.3 M 44 M 43.8 M 43.8 M 41.1 M 39.2 M 38.3 M 38 M 37.9 M 37.8 M 36.5 M 34.2 M 34 M 33.9 M 30.9 M 30.4 M 29.8 M 28.2 M 25.9 M 25.9 M 25.8 M 22.5 M 22.4 M 22.4 M 22.2 M 22.2 M 22.4 M

Net Income

-33.5 M 56.1 M - -30.9 M -25.4 M -33.5 M - -32.2 M -56 M -37.2 M - -37.8 M -37.3 M -33.7 M - -17.5 M -30.8 M -33 M - -22.7 M -28.6 M -35.1 M -37.3 M -38.5 M -33.3 M -29 M -29.2 M -16.5 M -14.5 M -24.3 M -23.5 M -39.5 M -33.7 M -30.1 M -16.6 M -7.48 M -14.4 M -53.5 M -19.6 M -14 M -66.7 M 66.7 M -19.8 M -19.9 M -16.7 M -18.7 M -20.7 M -18.3 M -18 M -16.6 M -1.84 M -13.9 M -13.6 M -10.5 M -7.73 M -13.3 M -8.54 M -8.9 M -10.2 M -6.51 M -5.29 M -6.54 M

Revenue

- 9.89 M - - - - - - - - - - - - - - - - - 30 M 28.8 M 21.1 M 10.6 M 26.1 M 13.5 M 23.5 M 33.4 M 29.9 M 26.8 M 21.8 M 22 M 4.61 M 1.66 M 1.59 M 13.8 M 21.7 M 17.2 M 12.3 M 12.9 M 11.3 M 10 M 7.42 M 6.68 M 3.26 M 3.19 M 388 K 180 K 214 K 45 K 100 K 169 K 196 K 140 K 1.1 M 1.58 M 1.42 M 1.53 M 1.5 M 1.14 M 987 K 1.16 M 1.24 M

Cost of Revenue

- 587 K - - - - - - - - - - - - - - - - - 333 K 342 K 263 K - 401 K 147 K 267 K - 278 K 55 K 131 K - 36 K 116 K 203 K - 184 K - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-32.4 M -17.4 M - -26.4 M -32.4 M -35 M - -35.4 M -59.2 M -39 M - -48.2 M -40.9 M -35.7 M - -50.8 M -37.4 M -35 M - -39.8 M -45.6 M -45.3 M -33.8 M -25.4 M -27.7 M -23.7 M -23.7 M -11.1 M -63.4 M -63.4 M -18.5 M -35.4 M -30.6 M -27.7 M -14.1 M -5.11 M -11.9 M -12.7 M -11.9 M -12 M -10.9 M -19.5 M -18 M -19.3 M -16 M -17.9 M -20 M -17.1 M -17.2 M -15.7 M -13.9 M -13.4 M -13.2 M -10 M -7.53 M -13 M -8.24 M -8.07 M -9.85 M -6.16 M -4.95 M -6.45 M

Interest Expense

- - - - - - - 4.05 M 9.22 M 8.23 M - 7.92 M 7.93 M 7.93 M - 4.93 M 4.93 M 4.94 M - 4.91 M 4.91 M 4.9 M - 6.88 M 5.98 M 5.9 M - 5.72 M 5.53 M 5.6 M - 4.6 M 3.68 M 2.82 M - 2.78 M 2.72 M 2.66 M - 2.14 M 1.86 M 1.38 M - 871 K 937 K 957 K - 944 K 939 K 672 K - 592 K 589 K 587 K - 413 K 453 K 494 K - 528 K 527 K 293 K

EBITDA

-32.2 M -17.2 M - -26.2 M -32.2 M -34.7 M - -35.2 M -59 M -38.8 M - -48 M -40.6 M -35.5 M - -50.5 M -37.2 M -34.8 M - -39.5 M -45.2 M -44.9 M -33.8 M -25 M -27.3 M -23.3 M -23.7 M -10.7 M -62.6 M -63 M -18.5 M -34.8 M -30.2 M -27.5 M -14.1 M -4.73 M -11.7 M -12.6 M -11.9 M -11.8 M -10.8 M -19.4 M -18 M -19.1 M -15.9 M -17.9 M -20 M -16.9 M -17.1 M -15.6 M -13.9 M -13.2 M -13 M -9.95 M -7.53 M -12.8 M -8.08 M -7.98 M -9.85 M -5.83 M -4.72 M -6.28 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - 41 M 40.5 M 40 M 32.3 M 29.3 M 27.9 M 26.8 M 29.1 M 25 M 24.8 M 23.3 M 20.9 M 26.9 M 24.7 M 22.6 M 19.2 M 18.3 M 20.2 M 17.3 M 17.3 M 15.8 M 14.1 M 13.6 M 13.3 M 11.1 M 9.12 M 14.5 M 9.77 M 9.57 M 11 M 7.15 M 6.1 M 7.69 M

General and Administrative Expenses

10.3 M 13.4 M - 10.4 M 10.3 M 11.1 M - 11.3 M 13.8 M 12.3 M - 16.4 M 11.3 M 11.1 M - 12.2 M 13.9 M 11 M - 14 M 15.5 M 12.8 M - 19.8 M 16.9 M 18 M - 16.9 M 16.9 M 14.6 M - 13.2 M 12.7 M 10.9 M - 11.7 M 15.8 M 12.5 M - 10.5 M 10.4 M 11.1 M - 9.05 M 7.89 M 8.99 M - 5.57 M 4.86 M 3.77 M - 4.21 M 3.74 M 3.99 M - 2.74 M 2.21 M 2.32 M - 1.83 M 2.03 M 2.26 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Omeros Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
AnaptysBio AnaptysBio
ANAB
$ 51.0 1.83 % $ 1.48 B usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Black Diamond Therapeutics Black Diamond Therapeutics
BDTX
$ 1.88 0.53 % $ 107 M usaUSA
Clovis Oncology Clovis Oncology
CLVS
- -7.23 % $ 13 M usaUSA
Concert Pharmaceuticals Concert Pharmaceuticals
CNCE
- - $ 401 M usaUSA
Evelo Biosciences Evelo Biosciences
EVLO
- -14.46 % $ 27.9 M usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 60.26 0.06 % $ 11.6 B usaUSA
BioNTech SE BioNTech SE
BNTX
$ 98.52 0.24 % $ 23.8 B germanyGermany
Can-Fite BioPharma Ltd. Can-Fite BioPharma Ltd.
CANF
$ 2.17 0.46 % $ 3.57 M israelIsrael
Freeline Therapeutics Holdings plc Freeline Therapeutics Holdings plc
FRLN
- - $ 384 M britainBritain
Genocea Biosciences Genocea Biosciences
GNCA
- -15.0 % $ 3.04 M usaUSA
Catalyst Biosciences Catalyst Biosciences
CBIO
$ 13.99 0.84 % $ 1.25 B usaUSA
C4 Therapeutics C4 Therapeutics
CCCC
$ 2.98 0.3 % $ 247 M usaUSA
Codexis Codexis
CDXS
$ 1.32 1.09 % $ 115 M usaUSA
Amryt Pharma plc Amryt Pharma plc
AMYT
- - $ 621 M britainBritain
Cerus Corporation Cerus Corporation
CERS
$ 2.62 0.38 % $ 499 M usaUSA
G1 Therapeutics G1 Therapeutics
GTHX
- - $ 370 M usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.13 0.43 % $ 132 M usaUSA
Celldex Therapeutics Celldex Therapeutics
CLDX
$ 31.1 1.16 % $ 2.07 B usaUSA
CollPlant Biotechnologies Ltd. CollPlant Biotechnologies Ltd.
CLGN
$ 4.25 3.16 % $ 51.9 M israelIsrael
Cellectar Biosciences Cellectar Biosciences
CLRB
$ 1.8 0.72 % $ 4.69 M usaUSA
AbbVie AbbVie
ABBV
$ 264.34 0.09 % $ 468 B usaUSA
Humanigen Humanigen
HGEN
- -81.12 % $ 4.28 M usaUSA
Cocrystal Pharma Cocrystal Pharma
COCP
$ 1.17 1.74 % $ 13.2 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 12.7 0.4 % $ 3.79 B canadaCanada
Abeona Therapeutics Abeona Therapeutics
ABEO
$ 5.4 2.65 % $ 286 M usaUSA
Collegium Pharmaceutical Collegium Pharmaceutical
COLL
$ 22.53 0.2 % $ 713 M usaUSA
Corcept Therapeutics Incorporated Corcept Therapeutics Incorporated
CORT
$ 116.1 4.93 % $ 12.1 B usaUSA
Фармсинтез Фармсинтез
LIFE
- - - russiaRussia
IGM Biosciences IGM Biosciences
IGMS
- - $ 76.9 M usaUSA
IMV IMV
IMV
- - $ 13.1 M canadaCanada
Kinnate Biopharma Kinnate Biopharma
KNTE
- - $ 123 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.24 0.74 % $ 82.9 M usaUSA
Checkmate Pharmaceuticals Checkmate Pharmaceuticals
CMPI
- - $ 231 M usaUSA
Corbus Pharmaceuticals Holdings Corbus Pharmaceuticals Holdings
CRBP
$ 7.14 0.19 % $ 95.1 M usaUSA
Karuna Therapeutics Karuna Therapeutics
KRTX
- - $ 12.2 B usaUSA
Curis Curis
CRIS
$ 0.83 1.1 % $ 10.9 M usaUSA
CorMedix CorMedix
CRMD
$ 7.85 1.03 % $ 565 K usaUSA
Crinetics Pharmaceuticals Crinetics Pharmaceuticals
CRNX
$ 84.95 0.13 % $ 7.99 B usaUSA
CRISPR Therapeutics AG CRISPR Therapeutics AG
CRSP
$ 54.23 0.23 % $ 4.88 B schweizSchweiz
Champions Oncology Champions Oncology
CSBR
$ 4.9 0.1 % $ 67.8 M usaUSA
Chimerix Chimerix
CMRX
- - $ 756 M usaUSA
Corvus Pharmaceuticals Corvus Pharmaceuticals
CRVS
$ 11.62 8.21 % $ 918 M usaUSA
Cue Biopharma Cue Biopharma
CUE
$ 31.41 1.45 % $ 2.98 B usaUSA
CEL-SCI Corporation CEL-SCI Corporation
CVM
$ 1.67 2.38 % $ 13.4 M usaUSA
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.85 0.2 % $ 929 M canadaCanada
Cytokinetics, Incorporated Cytokinetics, Incorporated
CYTK
$ 64.66 0.17 % $ 7.77 M usaUSA
Daré Bioscience Daré Bioscience
DARE
$ 0.78 4.73 % $ 8.72 M usaUSA
Adagene Adagene
ADAG
$ 2.93 2.86 % $ 173 M chinaChina
DiaMedica Therapeutics DiaMedica Therapeutics
DMAC
$ 7.94 1.4 % $ 373 M usaUSA